Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
23
ESLOF Quote, Financials, Valuation and Earnings
Last price:
$318.84
Seasonality move
:
2.89%
Day range:
$306.83 - $320.91
52-week range:
$232.00 - $376.38
Dividend yield:
1.4%
P/E ratio:
57.23x
P/S ratio:
4.97x
P/B ratio:
46.64x
Volume:
491
Avg. volume:
805
1-year change:
32.71%
Market cap:
$147B
Revenue:
$28.7B
EPS (TTM):
$5.68
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ESLOF
EssilorLuxottica SA
|
-- | -- | -- | -- | -- |
|
CLLS
Cellectis SA
|
$11.9M | -$0.11 | -5.7% | -56.58% | $7.20 |
|
DBVT
DBV Technologies SA
|
$1.2M | -$0.23 | -- | -80.11% | $40.03 |
|
IPHA
Innate Pharma SA
|
$2.6M | -- | -- | -- | $5.15 |
|
IVA
Inventiva SA
|
-- | -$0.18 | -- | -- | $15.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ESLOF
EssilorLuxottica SA
|
$318.84 | -- | $147B | 57.23x | $4.47 | 1.4% | 4.97x |
|
CLLS
Cellectis SA
|
$4.84 | $7.20 | $485.6M | -- | $0.00 | 0% | 6.02x |
|
DBVT
DBV Technologies SA
|
$19.17 | $40.03 | $524.5M | -- | $0.00 | 0% | -- |
|
IPHA
Innate Pharma SA
|
$1.75 | $5.15 | $161.3M | -- | $0.00 | 0% | 22.60x |
|
IVA
Inventiva SA
|
$4.65 | $15.33 | $678.2M | -- | $0.00 | 0% | 27.07x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ESLOF
EssilorLuxottica SA
|
-- | 0.464 | -- | -- |
|
CLLS
Cellectis SA
|
54.27% | 0.076 | 41.7% | 1.35x |
|
DBVT
DBV Technologies SA
|
23.24% | -3.671 | 5.85% | 1.41x |
|
IPHA
Innate Pharma SA
|
55.22% | -0.427 | -- | 2.76x |
|
IVA
Inventiva SA
|
-145.15% | -1.134 | 32.05% | 0.43x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ESLOF
EssilorLuxottica SA
|
-- | -- | -- | -- | -- | -- |
|
CLLS
Cellectis SA
|
$30M | $5.9M | -15.69% | -31.08% | 16.76% | -$4M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
IPHA
Innate Pharma SA
|
-- | -- | -39.78% | -72.79% | -- | -- |
|
IVA
Inventiva SA
|
-- | -- | -- | -- | -- | -- |
EssilorLuxottica SA vs. Competitors
-
Which has Higher Returns ESLOF or CLLS?
Cellectis SA has a net margin of -- compared to EssilorLuxottica SA's net margin of 1.68%. EssilorLuxottica SA's return on equity of -- beat Cellectis SA's return on equity of -31.08%.
Company Gross Margin Earnings Per Share Invested Capital ESLOFEssilorLuxottica SA-- -- -- CLLSCellectis SA85.76% $0.01 $219.7M -
What do Analysts Say About ESLOF or CLLS?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Cellectis SA has an analysts' consensus of $7.20 which suggests that it could grow by 48.76%. Given that Cellectis SA has higher upside potential than EssilorLuxottica SA, analysts believe Cellectis SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOFEssilorLuxottica SA0 0 0 CLLSCellectis SA2 2 0 -
Is ESLOF or CLLS More Risky?
EssilorLuxottica SA has a beta of 0.861, which suggesting that the stock is 13.853% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.823, suggesting its more volatile than the S&P 500 by 182.278%.
-
Which is a Better Dividend Stock ESLOF or CLLS?
EssilorLuxottica SA has a quarterly dividend of $4.47 per share corresponding to a yield of 1.4%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 76.01% of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOF or CLLS?
EssilorLuxottica SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $35M. EssilorLuxottica SA's net income of -- is lower than Cellectis SA's net income of $586.4K. Notably, EssilorLuxottica SA's price-to-earnings ratio is 57.23x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 4.97x versus 6.02x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOFEssilorLuxottica SA4.97x 57.23x -- -- CLLSCellectis SA6.02x -- $35M $586.4K
-
Which has Higher Returns ESLOF or DBVT?
DBV Technologies SA has a net margin of -- compared to EssilorLuxottica SA's net margin of --. EssilorLuxottica SA's return on equity of -- beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital ESLOFEssilorLuxottica SA-- -- -- DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About ESLOF or DBVT?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $40.03 which suggests that it could grow by 107.86%. Given that DBV Technologies SA has higher upside potential than EssilorLuxottica SA, analysts believe DBV Technologies SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOFEssilorLuxottica SA0 0 0 DBVTDBV Technologies SA4 0 1 -
Is ESLOF or DBVT More Risky?
EssilorLuxottica SA has a beta of 0.861, which suggesting that the stock is 13.853% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.166, suggesting its less volatile than the S&P 500 by 216.581%.
-
Which is a Better Dividend Stock ESLOF or DBVT?
EssilorLuxottica SA has a quarterly dividend of $4.47 per share corresponding to a yield of 1.4%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 76.01% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOF or DBVT?
EssilorLuxottica SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. EssilorLuxottica SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, EssilorLuxottica SA's price-to-earnings ratio is 57.23x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 4.97x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOFEssilorLuxottica SA4.97x 57.23x -- -- DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns ESLOF or IPHA?
Innate Pharma SA has a net margin of -- compared to EssilorLuxottica SA's net margin of --. EssilorLuxottica SA's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.
Company Gross Margin Earnings Per Share Invested Capital ESLOFEssilorLuxottica SA-- -- -- IPHAInnate Pharma SA-- -- $68.9M -
What do Analysts Say About ESLOF or IPHA?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Innate Pharma SA has an analysts' consensus of $5.15 which suggests that it could grow by 194.51%. Given that Innate Pharma SA has higher upside potential than EssilorLuxottica SA, analysts believe Innate Pharma SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOFEssilorLuxottica SA0 0 0 IPHAInnate Pharma SA3 2 0 -
Is ESLOF or IPHA More Risky?
EssilorLuxottica SA has a beta of 0.861, which suggesting that the stock is 13.853% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.018, suggesting its less volatile than the S&P 500 by 101.755%.
-
Which is a Better Dividend Stock ESLOF or IPHA?
EssilorLuxottica SA has a quarterly dividend of $4.47 per share corresponding to a yield of 1.4%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 76.01% of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOF or IPHA?
EssilorLuxottica SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. EssilorLuxottica SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, EssilorLuxottica SA's price-to-earnings ratio is 57.23x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 4.97x versus 22.60x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOFEssilorLuxottica SA4.97x 57.23x -- -- IPHAInnate Pharma SA22.60x -- -- --
-
Which has Higher Returns ESLOF or IVA?
Inventiva SA has a net margin of -- compared to EssilorLuxottica SA's net margin of --. EssilorLuxottica SA's return on equity of -- beat Inventiva SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ESLOFEssilorLuxottica SA-- -- -- IVAInventiva SA-- -- -$34.6M -
What do Analysts Say About ESLOF or IVA?
EssilorLuxottica SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Inventiva SA has an analysts' consensus of $15.33 which suggests that it could grow by 229.75%. Given that Inventiva SA has higher upside potential than EssilorLuxottica SA, analysts believe Inventiva SA is more attractive than EssilorLuxottica SA.
Company Buy Ratings Hold Ratings Sell Ratings ESLOFEssilorLuxottica SA0 0 0 IVAInventiva SA8 0 0 -
Is ESLOF or IVA More Risky?
EssilorLuxottica SA has a beta of 0.861, which suggesting that the stock is 13.853% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.708, suggesting its less volatile than the S&P 500 by 29.184%.
-
Which is a Better Dividend Stock ESLOF or IVA?
EssilorLuxottica SA has a quarterly dividend of $4.47 per share corresponding to a yield of 1.4%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EssilorLuxottica SA pays 76.01% of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend. EssilorLuxottica SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESLOF or IVA?
EssilorLuxottica SA quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. EssilorLuxottica SA's net income of -- is lower than Inventiva SA's net income of --. Notably, EssilorLuxottica SA's price-to-earnings ratio is 57.23x while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EssilorLuxottica SA is 4.97x versus 27.07x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESLOFEssilorLuxottica SA4.97x 57.23x -- -- IVAInventiva SA27.07x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Sell
50
NUTX alert for Jan 1
Nutex Health, Inc. [NUTX] is down 9.81% over the past day.
